SEARCH

SEARCH BY CITATION

References

  • ADACHI, Y., SUZUKI, H. & SUGIYAMA, Y. (2001). Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharma. Res., 18, 16601668.
  • AMBUDKAR, S.V., DEY, S., HRYCYNA, C.A., RAMACHANDRA, M., PASTAN, I. & GOTTESMAN, M.M. (1999). Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 39, 361398.
  • BISSERY, M.C., BOUCHARD, H., RIOU, J.F., VRIGNAUD, C., COMBEAU, J., BOURZAT, J.D., COMMERCON, A. & LAVELLE, F. (2000). Preclinical evaluation of TXD258, a new taxoid. Proceedings of the 91st American Association for Cancer Research, San Francisco, CA, April 1 – 5, Vol. 41, p. 214.
  • BISSERY, M.C., NOHYNEK, G., SANDERINK, G.J. & LAVELLE, F. (1995). Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs, 6, 339355, 363–368.
  • CLARKE, S.J. & RIVORY, L.P. (1999). Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet., 36, 99114.
  • DAGENAIS, C., ROUSSELLE, C., POLLACK, G.M. & SCHERRMANN, J.M. (2000). Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein deficient mice. J. Cerebr. Blood Flow Metab., 20, 381386.
  • DYKES, D.J., SARSAT, J.P. & BISSERY, M.C. (2000). Efficacy evalua-tion of TXD258, a taxoid compound against orthotopic and subcutaneous glioblastomas. Proceedings of the 91st American Association for Cancer Research, San Francisco, CA, April 1–5, Vol. 41, p. 301.
  • EISEMAN, J.L., EDDINGTON, N.D., LESLIE, J., MACAULEY, C., SENTZ, D.L., ZUHOWSKI, M., KUJAWA, J.M., YOUNG, D. & EGORIN, M.J. (1994). Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother. Pharmacol., 34, 465471.
  • FERLINI, C., DISTEFANO, M., PIGNATELLI, F., LIN, S., RIVA, A., BOMBARDELLI, E., MANCUSO, S., OJIMA, I. & SCAMBIA, G. (2000). Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors. Br. J. Cancer, 83, 17621768.
  • GIANNI, L., KEARNS, C.M., GIANI, A., CAPRI, G., VIGANO, L., LACATELLI, A., BONADONNA, G. & EGORIN, M.J. (1995). Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 13, 180190.
  • GOTTESMAN, M.M. & PASTAN, I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385427.
  • HEIMANS, J.J., VERMORKEN, J.B., WOLBERS, J.G., EELTINK, C.M., MEIJER, O.W., TAPHOORN, M.J. & BEIJNEN, J.H. (1994). Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann. Oncol., 5, 951953.
  • KLECKER, R.W., JAMIS-DOW, C.A., EGORIN, M.J., ERKMEN, K., PARKER, R.J., STEVENS, R. & COLLINS, J.M. (1994). Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague – Dawley rat. Drug Metab. Dispos., 22, 254258.
  • LESSER, G.J., GROSSMAN, S.A., ELLER, S. & ROWINSKY, E.K. (1995). The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemother. Pharmacol., 37, 173178.
  • LIN, S. & OJIMA, I. (2000). Recent strategies in the development of taxane anticancer drugs. Exp. Opin. Ther. Patents, 10, 869889.
  • MARTIN, C., BERRIDGE, G., HIGGINS, C.F., MISTRY, P., CHARLTON, P. & CALLAGHAN, R. (2000). Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol., 58, 624632.
  • ONETTO, N., CANETTA, R., WINOGRAD, B., CATANE, R., DOUGAN, M., GRECHKO, J., BURROUGHS, J. & ROZENCWEIG, M. (1993). Overview of Taxol safety. J. Natl. Cancer Inst. Monogr., 15, 131139.
  • PARDRIDGE, W.M., CONNOR, J.D. & CRAWFORD, I.L. (1975). Permeability changes in the blood – brain barrier: causes and consequences. C.R.C. Crit. Rev. Toxicol., 2, 159199.
  • ROMSICKI, Y. & SHAROM, F.J. (1999). The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry, 38, 68876896.
  • ROUSSELLE, C., CLAIR, P., LEFAUCONNIER, J.M., KACZOREK, M., SCHERRMANN, J.M. & TEMSAMANI, J. (2000). New advances in the transport of doxorubicin through the blood – brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol., 57, 679686.
  • SCHINKEL, A.H. (1999). P-glycoprotein, a gatekeeper in the blood – brain barrier. Adv. Drug. Deliv Rev., 36, 179194.
  • SMITH, Q.R. (1996). Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. In: Models for Assessing Drug Absorption and Metabolism. ed. Borchardt, R.T., Smith, P.L. & Wilson, G. pp. 285307. New York: Plenum Press.
  • SPARREBOOM, A., VAN TELLINGEN, O., NOOIJEN, W.J. & BEIJNEN, J.H. (1996). Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res., 56, 21122115.
  • STEIN, W.D. (1986). Transport and Diffusion Across Cell Membranes. Orlando, FL: Academic Press.
  • STEPHENS, R.H., O'NEILL, C.A., WARHURST, A., CARLSON, G.L., ROWLAND, M. & WARHURST, G. (2001). Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther., 296, 584591.
  • TAKASATO, Y., RAPOPORT, S.I. & SMITH, Q.R. (1984). An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol., 247, H484H493.
  • TRIGUERO, D., BUCIAK, J. & PARDRIDGE, W.M. (1990). Comparison of in vitro and in vivo models of drug transcytosis through the blood – brain barrier. J. Pharmacol. Exp. Ther., 253, 884891.
  • TSUJI, A. & TAMAI, I. (1997). Blood – brain barrier function of P-glycoprotein. Adv. Drug Del. Rev., 25, 287298.
  • VAN TELLINGEN, O., BEIJNEN, J.H., VERWEIJ, J., SCHERRENBURG, E.J., NOOIJEN, W.J. & SPARREBOOM, A. (1999a). Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin. Cancer Res., 5, 29182924.
  • VAN TELLINGEN, O., HUIZING, M.T., PANDAY, V.R., SCHELLENS, J.H., NOOIJEN, W.J. & BEIJNEN, J.H. (1999b). Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br. J. Cancer., 81, 330335.
  • VAN ZUYLEN, L., VERWEIJ, J. & SPARREBOOM, A. (2001). Role of formulation vehicles in taxane pharmacology. Invest. New Drugs., 19, 125141.
  • VERWEIJ, J., CLAVEL, M. & CHEVALIER, B. (1994). Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann. Oncol., 5, 495505.
  • VRIGNAUD, P., LEJEUNE, P., CHAPLIN, D., LAVELLE, F. & BISSERY, M.C. (2000). In vivo efficacy of TXD258, a new taxoid, against human tumor xenografts. Proceedings of the 91st American Association for Cancer Research, San Francisco, CA, April 1–5, Vol. 41, p. 214.
  • YAMAZAKI, M., NEWAY, W.E., OHE, T., CHEN, I., ROWE, J.F., HOCHMAN, J.H., CHIBA, M. & LIN, J.H. (2001). In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther., 296, 723735.